ADMD – Watch out!

I just wanted to talk to you guys about Advanced Medical Isotope Corporation (ADMD): engages in the production and distribution of medical isotopes and medical isotope technologies.

Pros: Tons of news talking about this company being the only one of its kind about to go into production of these medical isotopes that everyone needs. Has no real competitors because all competitors are foreign.

Seekingalpha: “Through a determined strategy of growth that keys in on the production and distribution of medical isotopes and medical isotope technologies, Advanced Medical Isotope has managed to become a relevant name in the rapidly-growing field of nuclear medicine. It was, however, the recent acquisition of a key license to an exclusive technology that may have positioned the company to become the U.S. leader in the field of medical isotopes.” – Taken from a seekingalpha.com article.

Cons:

There is something about their key executive that makes me not want to invest in ADMD even though it should become really big: James C. Katzaroff. He is connected to 24 board members in 5 different organizations across 4 different industries.

He has been Chief Executive Officer of Tesla Vision Corp. (alternate name, Manakoa Services Corporation) since November 14, 2005 and serves as its Acting Treasurer. – Manakoa Services no longer exists. And Tesla Vision I think was delisted.

Mr. Katzaroff has been Chairman and Chief Executive Officer of Apogee Biometrics, Inc. since December 2001. – I can’t find anything online about Apogee Biometrics. I am not sure if this company even exists anymore.

Former Chief Executive Officer and Director - Electronic Identification Inc. - But this doesn’t exist anymore too.
I was planning to do more research about this guy, but after all of the stuff I found. Its probably better for me to invest in a company I feel safer with. Maybe he is a good guy and he just has bad luck. Or he’s a crook that goes through companies and takes their money and starts new companies.
Disclaimer: Nothing I say should be taken as investment advice. You can do whatever you want to do. At the end of the day, you made that decision, not me. I just provided you with another outlook.
Posted in Investments | Tagged | Leave a comment

3 Reasons Pfizer Should Partner With MannKind

By Max Macaluso
August 23, 2012

The odds of Pfizer (NYSE: PFE ) bringing MannKind’s (Nasdaq: MNKD ) inhalable insulin drug to market seem as slim as Barry Manilow recording a Christmas album with Marilyn Manson.

Pfizer already tried to enter this market and failed miserably. Nevertheless, there are three main reasons why it should partner with MannKind, and several reasons why investors should be watching both of these companies.

1. Pfizer should forget about Exubera
Pfizer commercialized Nektar Therapeutics’ (Nasdaq: NKTR ) inhalable insulin product, Exubera, in 2006, and the collaboration was a massive failure. Pfizer discontinued the drug after just a year and this project resulted in a loss close to $3 billion.

While Exubera and MannKind’s drug, Afrezza, both deliver insulin through an inhalation device, they are far from the same product. MannKind founder and CEO Alfred Mann has been trying to distance his company’s drug from Exubera since the latter was pulled from the market. I discussed some of the differences between these drugs in a previous article; in a nutshell, Exubera lacked any clinical advantage over injected insulin and the device was just too big to appeal to patients. Based on its recent trials, however, Afrezza biologically acts faster than the injectable insulin currently available, and the device is small enough to fit in your pocket.

Pfizer should forget about its financial failure with Exubera, remember its missteps while bringing it to market, and apply this experience toward the successful launch of Afrezza. The market size for fast-acting insulin is well worth a second chance. Eli Lilly’s (NYSE: LLY ) Humalog insulin sales, for instance, reached almost $2.4 billion in fiscal 2011.

2. MannKind needs a partner yesterday
MannKind is in a tough financial situation. According to its latest financial statements, the company is spending about $8.4 million a month and doesn’t have any recurring revenue. CFO Matthew Pfeffer said the company would be spending more money in upcoming quarters as it completes the Afrezza clinical trials and gears up for a possible commercial launch. However, at the current burn rate, MannKind only has enough cash, cash equivalents, and short-term investments to cover about four months of operating expenses. An additional loan from Mann would help pay for costs over the short term, but MannKind will need a larger pharmaceutical company to market and sell Afrezza if it is approved.

Pfizer’s free cash flow during the last quarter topped $3.7 billion, while MannKind’s current market cap is only around $480 million. Pfizer clearly has the financial muscle to either license MannKind’s technology or obtain its intellectual property through an outright acquisition.

3. Pfizer needs a new blockbuster
Based on Pfizer’s latest earnings report, the company is facing a new set of challenges and would benefit from MannKind’s innovative technology. Pfizer’s year-over-year net income increased by 25% in the latest quarter, but this was mostly due to lower R&D and SG&A expenses. Revenue decreased from $16.5 billion to $15.1 billion.

This significant decline was caused by lower sales of Pfizer’s cholesterol medicine, Lipitor. The drug went off patent in 2011, and generic versions produced by Ranbaxy Laboratories and Mylan Laboratories caused Pfizer’s Lipitor sales to drop from $2.5 billion in Q2 of 2011 to $1.2 billion this quarter. Indian drugmaker Dr. Reddy’s recently announced its own version of Lipitor, so expect Pfizer’s sales to decrease again next quarter.

Cutting expenses is a good short-term strategy, but Pfizer will have to fill that hole in its revenue with another blockbuster. Pfizer could leverage MannKind’s inhalation technology to improve its existing products and create another top-selling drug. For instance, think about the market potential of an inhalable Lipitor or, better yet, an inhalable Viagra. It currently takes Pfizer’s little blue pill 30 minutes to a full hour to work its magic, but MannKind has demonstrated that its Dreamboat inhaler and powder technology have remarkably fast drug absorption. While there has been some interest in developing inhalable erectile dysfunction products, none are currently on the market. Viagra delivered through the Dreamboat would undoubtedly buoy Pfizer’s sales.

What could this mean for your portfolio?
Pfizer could benefit from MannKind’s technology in the long run, but the stock won’t crumble if a partnership doesn’t materialize soon. Pfizer has suffered in recent years as the patents of its prominent blockbuster drugs started to expire. However, the company is planning to spin off its animal health unit, divested its nutrition group, and is putting its energy toward what it does best: pharmaceuticals. It looks like Pfizer is starting to turn things around, so I’ll be closely tracking its R&D pipeline and might jump into this stock later this year.

A partnership for MannKind, on the other hand, would turn the tide for this beleaguered company. MannKind’s flagship drug, Afrezza, is completing clinical trials to satisfy FDA approval, and a cash influx from an outside investor would help it finish the trials and prepare a marketing campaign. In MannKind’s latest earnings call, Mann said the company is exploring various collaboration and funding opportunities, but nothing has been finalized. News of a partnership, with or without Pfizer, would undoubtedly cause the share price to surge.

Pharmaceutical stocks like MannKind are some of the riskiest investments on the market, so it’s always a good idea to diversify your holdings with some more stable stocks. However, if you want to learn more about another emerging drug opportunity, check out our brand-new premium report on Arena Pharmaceuticals. The company has a potential blockbuster in its recently approved obesity treatment. However, plenty of obstacles still stand in its way. Read all about it in our report, which comes with a full year of updates from one of our top health care analysts. Click here to claim your copy.

Posted in Investments | Tagged | Leave a comment

A FASTer FDA?

The Faster Access to Specialized Treatments (FAST) Act made its debut on the floor of the US House of Representatives earlier this month. The bill is seeking to extend fast-tracked drug approvals beyond HIV/AIDS and cancer drugs, which already benefit from legislation that have increased investment, shortened timeframes, and decreased burdens of proof for garnering US Food and Drug Administration approval.

The FDA is cautioning patience because in order to accelerate the approval of drugs that treat Parkinson’s, Alzheimer’s, diabetes, and other diseases, scientifically meaningful clinical endpoints must first be established to ensure that the right safety and efficacy data is be submitted and evaluated. “We agree with the sentiment behind [the FAST Act] but have to avoid inadvertently lowering the efficacy standard,” said director of the FDA’s Center for Drug Evaluation and Research Janet Woodcock at a Congressional subcommittee hearing on last Thursday (March 8).

But John Maraganore, CEO of Alnylam Pharmaceuticals, told the same subcommittee that the benefits of the FAST Act could be great when those endpoints are agreed upon and can consistently be measured to demonstrate a reasonable likelihood of clinical benefit. “If the accelerated approval pathway is modernized, and that is reduced to actual practice so people can see it, you can logically expect investors to feel more bullish about investing in biotech,” Maraganore told BioCentury. “As a result, I would expect more investment in breakthrough medicines, and more medicines coming into the pipeline that would take advantage of the accelerated or traditional pathways.”

The FAST Act will be further debated by the House of Representatives, and the ideas it contains could be absorbed into the Prescription Drug User Fee Act (PDUFA) V, which expires in September and is expected to be reauthorized.

Posted in Uncategorized | Leave a comment

How I Made It: Alfred Mann, entrepreneur and philanthropist

The billionaire has no formal business training but has demonstrated a knack for capitalizing on investment opportunities. His secret: Identify an unmet need and come up with a technology to fill it.

October 09, 2011|By Duke Helfand, Los Angeles Times

The gig: Alfred E. Mann, 85, is an aerospace and biomedical entrepreneur who founded 17 companies over six decades and became a billionaire philanthropist.

Niche man: Although he had no formal business training, Mann has demonstrated a knack for capitalizing on investment opportunities. His secret: Identify an unmet need and come up with a technology to fill it.

The result has been a string of companies with names like Spectrolab, Heliotek, MiniMed and Advanced Bionics. Mann has developed pacemakers, cochlear implants, insulin pumps and other devices.

Big payoff: Launching businesses and selling them has made Mann a fortune. Forbes put his net worth at $1 billion earlier this year. But the entrepreneur known to his friends as Al says wealth has never been a priority. “I’ve got more money than I can spend,” he said. “For me, the satisfaction of changing someone’s life — indeed, even giving a person back a useful life — that’s what really drives me.”

High school passion: Mann never dreamed of becoming an entrepreneur during his childhood in Portland, Ore. He was the middle of three children born to immigrant parents — his English father was a grocer and his Polish mother was a singer and pianist. Mann played cello, oboe and piano. (His favorite piano piece was the Rachmaninoff Prelude in C sharp minor.)

Science bound: His true calling emerged during his senior year of high school, when he took chemistry and physics. “That changed my life,” he said. (Even though he was the class co-valedictorian, he asked permission to stay an additional semester to take more physics. The school said no.)

Go Bruins: Mann went on to earn bachelor’s and master’s degrees in physics at UCLA, eventually setting down roots in Los Angeles. In 1956 he founded his first company, Spectrolab, which developed solar-power electric systems for spacecraft.

Spaceships to stethoscopes: Mann’s career took a turn in the late 1960s when researchers from Johns Hopkins University ask for help applying space technology to create a long-lasting pacemaker. Mann’s first biomedical company, Pacesetter Systems, was born. “I got intrigued by medicine,” he said.

Family Mann: As his business life grew, so did his family. The budding entrepreneur would marry four times over the ensuing decades, raising seven children who have given him nine grandchildren and one great-grandchild.

Mr. Philanthropy: Mann says he has given away about $500 million primarily to support research causes. Among his beneficiaries is the Alfred Mann Foundation, a nonprofit organization based on the sprawling grounds of the Mann Biomedical Park in Santa Clarita . It develops medical devices — such as the cochlear implant and an artificial pancreas — with the aim of bringing inventions to the marketplace.

Mann also has endowed biomedical research institutes at Purdue University, the Technion-Israel Institute of Technology and USC, bypassing alma mater UCLA to give its rival $163 million. “My objective is to solve medical problems,” he said.

Tough times: Mann has struggled to realize one of his dreams — the creation of a powder insulin inhaler for diabetics. The federal Food and Drug Administration declined to approve the treatment, Afrezza, twice last year and has asked for additional tests.

Mann said he has invested $925 million in MannKind Corp., which is developing the inhaler system. The company recently laid off 181 employees, leaving a workforce of about 250.

Meanwhile, Eclipse Aviation Corp. — an aircraft company in which he invested more than $100 million — went into bankruptcy.

Torrid pace: At this stage of life, Mann could be relaxing, playing rummy with Claude, his wife of eight years, at home in Las Vegas or in their other home on Mulholland Drive in Los Angeles. Instead he’s working 70 to 80 hours a week, spending half of each month crossing the country in one of his three private planes.

Mann allows himself two vacations a year — one week in Maui around Christmas and another week in Mexico for his wedding anniversary in February.

He plans to leave his money to healthcare research. But that’s in the future. Right now, he shows few signs of slowing down. “I’m going faster than ever,” he said. “It’s insane. Absolutely insane.”

duke.helfand@latimes.com

Posted in Business, Current News, Investments | Leave a comment

GPL – Reasonably Priced Growth Stock

Using data from finviz.com, (be sure to check the financial numbers on these companies on your own before any investing or trading in them) we ran a screen with numerous factors to narrow down the list of stocks:

-Optionable & Shortable

-Market Capitalization Over $300 Million

-Average Daily Volume Over 500k

-Price/Earnings (PE) Ratio Under 30

-Sales Growth Quarter-Over-Quarter (Q/Q) Over 25%

-Return On Assets (ROA) Over 20%

-Return On Equity (ROE) Over 20%

-Return On Investment (ROI) Over 20%

-Gross Profit Margin Over 20%

-Operating Margin Over 20%

-Net Profit Margin Over 20%

Great Panther Silver (GPL) - Canadian based miner, this is a fairly small cap name and low priced stock that barely made it through our screen – always be a bit more cautious and thorough when dealing with stocks below $5/share and also those with smaller market caps. Next reporting due mid-February.

Comment by Indianmark: Great Panther has the greatest gain for 2012, but the greatest gain lies ahead. The deeper they go the richer the veins. They will be mining silver for our grandchildren. With its low cap and silver’s low price, GPL’s future price could be very exciting.

Posted in Investments | Tagged | Leave a comment

Gold (GLD) and Silver (SLV) Surge After Fed Statement

On Wednesday, gold   futures for February delivery jumped $35.60 to settle at $1,700.01 per ounce, while silver   futures surged $1.15 to close at $33.12.

Both precious metals received a jolt from the Federal Reserve’s latest statement.  The Federal Reserve announced on Wednesday that it will not increase its benchmark interest rate until at least late 2014, saying that record-low rates are still needed to help boots the still sluggish economy.  After a two-day meeting of theFederal Open Market Committee, the central bank said the economy is growing moderately, despite slowing global growth.

Investor Insight: Should Apple Buy Gold?

Economists believe the extended time frame for low rates could lead to further Fed action to try to stimulate the economy, but today the Fed held off on any further bond-buying programs to fuel growth.  Other than pledging to keep its key rate at a record low well beyond the earlier mid-2013 target, the central bank’s statement today closely tracked its previous comments about economic conditions, using the same language to describe Europe’s debt problems and their impact on the global economy.

While the Fed’s latest statement ensures negative interest rates and U.S. dollar devaluation for the coming years, gold and silver investments jumped on the news.  In afternoon trading, the SPDR Gold Trust increased 2.6 percent, while the iShares Silver Trust jumped more than 4 percent.  Gold miners such as Barrick Gold and Newmont Mining gained 6.5 percent and 4.7 percent, respectively.  Shares of Yamana Gold   surged more than 10 percent.  Silver miners such as First Majestic and Endeavour Silver both climbed more than 6 percent.

“We were all under the assumption that rates would be held at a low level until 2013, but now with the date extended to 2014, it’s inherently bullish for gold,” said Ralph Preston, senior market analyst with Heritage West Financial.

If you would like to receive more professional analysis on equity miners and other precious metal investments, we invite you to try our premium service free for 14 days.

To contact the reporter on this story: Eric McWhinnie at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com

Posted in Investments | Leave a comment

GPL – Target Price $3.50-5

GPL: With the market up more than ever after a long streak of down days, we are looking for undervalued silver stocks. One stock we feel is very undervalued with a huge potential in upside is (GPL); Great Panther Silver Limited, together with its subsidiaries, engages in the acquisition, exploration, and development of precious and base metal properties in Mexico. From a technical standpoint, GPL is definitely over sold and has the potential to break-out very soon. The company as a whole shows tremendous growth in the near future and is definitely a company to be watching. The upside is that GPL is a very cheap stock and we could definitely see this stock over $3-5 by next year.

VANCOUVER, BRITISH COLUMBIA–(Marketwire -11/30/11)- Great Panther Silver Limited (TSX: GPR.TO - News)(AMEX: GPL -News) (“the Company”) is pleased to announce that underground drilling programs at the Company’s wholly owned Guanajuato Mine have been successful in confirming continuity of the Santa Margarita gold-silver vein plus two footwall veins between the 435 and 500 metre levels, and in extending the Guanajuatito silver-gold mineralization below the 100 metre level, down to the 390 metre level (see also news release January 27, 2011).

VANCOUVER, BRITISH COLUMBIA–(Marketwire -11/14/11)- GREAT PANTHER SILVER LIMITED (TSX: GPR.TO - News)(AMEX: GPL - News) (or “the Company”) announces the financial results for the three and nine months ended September 30, 2011. Great Panther is pleased to report revenues for the nine months ended September 30, 2011 of $40.3 million, representing a 42% increase over the same period in the prior year. The Company also significantly grew earnings from mining operations to $20.9 million for the nine month period, a 97% increase over the comparable period in 2010. Revenues for the three months ended September 30, 2011 increased by 46% to a record $16.3 million, while earnings from mining operations increased by 78% to $8.3 million. Working capital increased to $53.8 million from $18.8 million at December 31, 2010. The full version of the financial statements and management’s discussion and analysis can be viewed on the Company’s website atwww.greatpanther.com or on SEDAR at www.sedar.com.

Disclaimer: We have a position in GPL. We are not liable for anything you purchase.

Posted in Silver, Uncategorized | Tagged | Leave a comment

GPL – Stock Earnings

VANCOUVER, BRITISH COLUMBIA–(Marketwire -11/14/11)- GREAT PANTHER SILVER LIMITED (TSX: GPR.TO - News)(AMEX: GPL - News) (or “the Company”) announces the financial results for the three and nine months ended September 30, 2011. Great Panther is pleased to report revenues for the nine months ended September 30, 2011 of $40.3 million, representing a 42% increase over the same period in the prior year. The Company also significantly grew earnings from mining operations to $20.9 million for the nine month period, a 97% increase over the comparable period in 2010. Revenues for the three months ended September 30, 2011 increased by 46% to a record $16.3 million, while earnings from mining operations increased by 78% to $8.3 million. Working capital increased to $53.8 million from $18.8 million at December 31, 2010. The full version of the financial statements and management’s discussion and analysis can be viewed on the Company’s website atwww.greatpanther.com or on SEDAR at www.sedar.com.

“We are extremely pleased that our financial results continue to show significant growth in our revenues and earnings,” stated Robert Archer, President and CEO. “The partial draw-down of concentrate inventory at Guanajuato during the latter half of the third quarter resulted in near-normal shipments for the period and brought stability back to our revenue stream.”

“Recent discoveries of high grade silver and gold mineralization have been accessed in an extention of our Cata Mine in Guanajuato, which should contribute to higher grades and improved metal output in the coming quarters,” added Mr. Archer. “In addition, we are very excited about the prospects for our San Ignacio and Santa Rosa properties which are located within trucking distance to our Guanajuato Mine Complex. The initial resource estimate at San Ignacio is an excellent start in proving up this new discovery for Great Panther, and we have accelerated our drilling program as a result.”

2011 THIRD QUARTER HIGHLIGHTS

 

--  46% increase in revenue to a record $16.3 million.

--  78% increase in gross profit (earnings from mining operations) to $8.3
    million.

--  81% increase in Adjusted EBITDA (refer to "Non-GAAP Measures" below) to
    $7.9 million.

--  12% increase in net income to $3.4 million ($0.03 per share).

--  Cash and cash equivalents increased to $35.1 million at September 30,
    2011, from $14.0 million at December 31, 2010.

--  Working capital has increased to $53.8 million.

--  Consolidated cash cost per ounce of silver, net of by-product credits,
    was US$9.02, a 33% increase from Q3 2010 but a 24% decrease from the
    second quarter 2011.

--  16% increase in plant throughput at both operations to 53,375 tonnes
    from 46,039 tonnes for the third quarter 2010.

--  18% decrease in overall metal production to 484,550 silver equivalent
    ounces ("Ag eq oz") from 588,454 Ag eq oz for third quarter of 2010.

--  2% decrease in overall metal production to 1.65 million Ag eq oz for the
    nine-months ended September 30, 2011 compared to a year ago. This
    decrease is mainly due to lower grades at the Company's Guanajuato mine
    during the third quarter of 2011.

--  On July 12, 2011, the Company purchased the new Santa Rosa silver-gold
    project totalling 1,514 hectares, approximately 10 to 15 kilometres
    northeast of Guanajuato, Mexico for US$1.5 million, subject to a 1.3%
    NSR, thereby increasing land holdings in Guanajuato by 136%.

--  On August 30, 2011, the Company announced the discovery of additional
    high grade silver-gold mineralization in an extension of the Cata Mine
    in the core of the Company's Guanajuato Mine Complex.

After the end of the third quarter, the Company announced the following
developments:

--  On October 11, 2011, the Company reported an initial NI 43-101 compliant
    mineral resource estimate, comprising Inferred Mineral Resources of 4.5
    million Ag eq oz, for its San Ignacio project in Guanajuato.

--  On October 13, 2011, the Company reported third quarter production
    figures and revised its production guidance for fiscal 2011 to
    approximately 2.2 million Ag eq oz.

--  On October 19, 2011, the Company extended the strike length of the
    silver-gold veins at its San Ignacio property in Guanajuato by 50% or
    150 metres.

                                             Change                  Change
                                               from                    from
                                                        9 Months   9 Months
                                                           Ended      Ended
Highlights                                                Sep 30,    Sep 30,
                                 Q3 2011    Q3 2010         2011       2010
---------------------------------------------------------------------------

Revenue                     $ 16,278,360        46% $ 40,298,334        42%
Earnings from mining
 operations                 $  8,320,291        78% $ 20,883,741        97%
Net income                  $  3,414,641        12% $ 12,924,669        54%
Adjusted EBITDA (1)         $  7,880,307        81% $ 18,748,200        93%

Earnings per share - basic  $       0.03         0% $       0.10        43%
Earnings per share -
 diluted                    $       0.02       -33% $       0.10        43%
Silver ounces produced
 (excluding equivalent           343,768       -10%    1,140,618        -1%
ounces of gold, zinc and
 lead)
Silver equivalent ounces
 produced (2)                    484,550       -18%    1,654,719        -2%
Silver payable ounces (3)        364,684         0%      907,037       -14%
Total cash cost per silver
 ounce (USD) (4)            $       9.02        33% $      10.02        41%
Average revenue per silver
 ounce sold                 $      35.38        63% $      36.36        89%

(1) “Adjusted EBITDA” is a non-IFRS measure in which standard EBITDA (earnings before interest expense, taxes, and depreciation and amortization) is adjusted for stock-based compensation expense, foreign exchange gains or losses, and non-recurring items. Refer to the “Non-IFRS Measures” section for a reconciliation of standardized and adjusted EBITDA to the financial statements.

(2) Silver equivalent ounces in 2011 were established using prices of US$1,200 per oz of gold, US$20 per oz of silver, US$0.90 per lb of lead, and US$0.90 per lb of zinc.

(3) Silver payable ounces represent the silver sold during each period. Due to the partial drawdown of concentrate inventory in the third quarter, the silver payable ounces is higher than the silver ounces produced for the period.

(4) “Cash cost per silver ounce” is a non-IFRS measure and is used by the Company to manage and evaluate operating performance at each of the Company’s mines and is widely reported in the silver mining industry as a benchmark for performance, but does not have a standardized meaning. Refer to the “Non-IFRS Measures” section.

OUTLOOK

Following four years of rapid growth in metal production, the first nine months of 2011 has been a period of consolidation. Throughput has continued to climb by over 20%, however this has been off-set by a drop in ore grades at both operations. The latter is being addressed and management expects an improvement in grades in the coming quarters.

Key to the success of the Company’s growth strategy is the delineation of new NI 43-101 compliant Mineral Resources and continuous improvements in mine production. To this end, exploration drilling has been accelerated, mineral resources have been added, and further resource updates are expected in the following quarters. The 2012 mine plans will be confirmed once the drill results for the current programs have been interpreted, and mineral resources are updated. Published resources do not include estimates for the Guanajuatito area and these will be included in the upcoming resource update. The Company continues to work towards achieving the goals of its growth strategy for its operations.

High grade silver-gold mineralization has been discovered in an extension of the Cata Mine in the core of the Guanajuato Mine Complex. The discovery was made during the course of a detailed deep drilling program being conducted at 12.5 to 25 metre intervals from several drill stations in the Cata Mine access ramp at the 510 metre level, the deepest mining development to date. The drilling program, covering an area of approximately 70 metres down-dip and 100 metres along strike, has been successful in extending silver-gold mineralization below the current level of mining and the existing mineral resource/reserve estimate. Highlights of the discovery include Alto 2 zone intersections from UG11-135 that returned 29.44g/t gold and 6,447g/t silver over a width of 3.20 metres, and UG11-137 that returned 7.38g/t gold and 2,114g/t silver over a width of 5.40 metres. The Alto 1a zone in UG11-137 returned 1.82g/t gold and 485g/t silver over a width of 4.80 metres, while the Veta Madre zone in UG11-133 returned 6.02g/t gold and 1,347g/t silver over a width of 2.25 metres. These zones have already been accessed by mine development and management believes that they will contribute to improved grades during the fourth quarter and into 2012.

The NI 43-101 compliant Mineral Resource for Topia supports current and future mine expansions and the plant capacity has been increased to accommodate the planned expansions. The NI 43-101 resource estimates for Guanajuato support current production and plant capacity has already exceeded what is required to achieve the future targets.

Drilling has been accelerated at the San Ignacio advanced exploration property, where an initial mineral resource estimate of 4.5 million Ag eq oz has been released (see news release dated October 11, 2011). Seven silver-gold mineralized zones, some stretching over the 450 metre strike length of the present drilling and up to nine metres true width, have been identified. The mineralization remains open over the entire four kilometre property. Further updates will be released as new results are compiled and interpreted. This and the prospective Santa Rosa property provide significant upside potential for future growth for the Guanajuato operations.

During the second quarter the Company experienced delays in concentrate shipments from its Guanajuato mine because of issues stemming from its metal trader’s smelter. In response to those delays the Company has been working directly with other metal traders and smelters to sell the excess inventory. Consequently, during the third quarter, the Company has made new arrangements to sell additional concentrates from the Company’s Guanajuato operations. The Company expects that these arrangements will enable the sale of the majority of the excess concentrate inventory through the remainder of 2011.

For the first nine months of 2011, the Company’s overall metal production was 1.65 million Ag eq oz as compared to 1.69 million Ag eq oz for the same period in 2010. Production for the fourth quarter is expected to improve to 550,000 Ag eq oz for a year-end total of approximately 2.2 million Ag eq oz. Production targets for 2012 and beyond are currently under review and management expects to provide further guidance late in the fourth quarter.

CONFERENCE CALL TO REVIEW THIRD QUARTER 2011 FINANCIAL RESULTS

The Company will hold a conference call to discuss the financial results tomorrow, November 15, at 7 AM Pacific Time 10:00 AM Eastern Time. Hosting the call will be Mr. Robert Archer, President and Chief Executive Officer and Mr. Martin Carsky, Executive Vice President and Chief Financial Officer.

Management welcomes interested shareholders, analysts, investors and media to join the live conference call by dialing just prior to the starting time.

Dial in number (Toll Free): 1-877-407-9205

Dial in number (International): +1-201-689-8054

No passcode is required

Replay number (Toll Free): 1-877-660-6853

Replay number (International): +1-201-612-7415

Replay Passcodes (both are required for playback):

Account #: 286

Conference ID #: 382663

A replay of the teleconference call will be available on November 15, 2011 from 10:00 AM Pacific Time, 1:00 PM Eastern Time until November 29, 2011 by dialing the numbers above. In addition, the call will be archived on the Company’s website.

INTERNATIONAL FINANCIAL REPORTING STANDARDS

The financial results discussed in this press release have been prepared in accordance with IFRS standards applicable to the preparation of interim financial information as required for all publicly traded companies in Canada in 2011. Readers should note that some comparative figures in this press release and the Company’s financial statements and Management Discussion and Analysis (“MD&A”) have been restated to reflect IFRS. Please refer to the Company’s Condensed Consolidated Interim Financial Statements and MD&A for the three and nine months ended September 30, 2011 for a detailed description of the Company’s accounting policies under IFRS and for disclosures and reconciliation of the impact of IFRS on previously reported results.

NON-GAAP MEASURES

The discussion of financial results in this press release includes reference to Adjusted EBITDA and Cash Cost per Ounce which are non-GAAP measures. The Company provides these measures to provide additional information regarding Company’s financial results and performance. Please refer to the Company’s MD&A for the three and nine months ended September 30, 2011 for a definition and reconciliation of these measures to reported GAAP results.

ABOUT GREAT PANTHER

Great Panther Silver Limited is a profitable, primary silver mining and exploration company listed on the Toronto Stock Exchange, trading under the symbol GPR and on the NYSE Amex, trading under the symbol GPL. The Company’s current activities are focused on the mining of precious and base metals from its two wholly-owned operating mines in Mexico. In addition, the Company is also pursuing acquisition opportunities throughout Latin America to add additional mines to its portfolio of properties. Great Panther’s mission is to become a leading primary silver producer by acquiring, developing and profitably mining precious metals.

All shareholders have the ability to receive a hard copy of the Company’s complete audited financial statements free of charge upon request. Should you wish to receive Great Panther Silver’s Financial Statements or the Annual Report on Form 20-F in hard copy, please contact us at the Company toll free at 1-888-355-1766 or 604-608-1766, or e-mail info@greatpanther.com.

For further information, please visit the Company’s website at www.greatpanther.com, contact B&D Capital at telephone 604-685-6465, fax 604-899-4303 or e-mail info@greatpanther.com.

ON BEHALF OF THE BOARD

Robert A. Archer, President & CEO

Kaare G. Foy, Executive Chairman

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of the Securities Act (Ontario) (together, “forward-looking statements”). Such forward-looking statements may include but are not limited to the Company’s plans for production at its Guanajuato and Topia Mines in Mexico, exploring its other properties in Mexico, the overall economic potential of its properties, the availability of adequate financing and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements expressed or implied by such forward-looking statements to be materially different. Such factors include, among others, risks and uncertainties relating to potential political risks involving the Company’s operations in a foreign jurisdiction, uncertainty of production and cost estimates and the potential for unexpected costs and expenses, physical risks inherent in mining operations, currency fluctuations, fluctuations in the price of silver, gold and base metals, completion of economic evaluations, changes in project parameters as plans continue to be refined, the inability or failure to obtain adequate financing on a timely basis, and other risks and uncertainties, including those described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2010 and reports on Form 6-K filed with the Securities and Exchange Commission and available at www.sec.gov and Material Change Reports filed with the Canadian Securities Administrators and available at www.sedar.com.

 

Great Panther Silver Limited

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(Expressed in Thousands of Canadian Dollars, except per share data)

September 30, 2011, December 31, 2010 and January 1, 2010 (Unaudited)

----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                 September 30,   December 31,     January 1,
                                          2011           2010           2010
----------------------------------------------------------------------------

Assets

Current assets:
    Cash and cash equivalents   $       35,074 $       13,967 $       13,312
    Restricted cash                        120            151              -
    Investments                             49            200             23
    Trade and other receivables         14,612          9,635          5,539
    Income taxes recoverable               296            239            342
    Inventories                          6,636          2,615          1,438
    Prepaid expenses, deposits
     and advances                        1,868          1,240          1,585
----------------------------------------------------------------------------
                                        58,655         28,047         22,239
Non-current assets:
    Mineral properties, plant
     and equipment                      36,345         27,277         19,212
    Intangible assets                      513            127            102
----------------------------------------------------------------------------
                                        36,858         27,404         19,314

----------------------------------------------------------------------------
                                $       95,513 $       55,451 $       41,553
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Liabilities and Shareholders'
 Equity

Current liabilities:
    Trade and other payables,
     including derivatives      $        4,664 $        4,758 $        2,631
    Capital lease obligations              208            369            801
    Promissory notes                         -            373            122
    Convertible loan notes                   -          3,716              -
    Current tax liability                    -             19             27
----------------------------------------------------------------------------
                                         4,872          9,235          3,581
Non-current liabilities:
    Capital lease obligations                -            128             63
    Promissory notes                         -             77            118
    Convertible loan notes                   -              -          3,103
    Reclamation and remediation
     provision                           1,758          1,955          2,086
    Deferred tax liability                   -              -          2,162
----------------------------------------------------------------------------
                                         1,758          2,160          7,532
Shareholders' equity:
    Share capital                      117,601         83,470         75,910
    Reserves                             5,378          7,607         12,211
    Deficit                           (34,096)       (47,021)       (57,681)
----------------------------------------------------------------------------
                                        88,883         44,056         30,440
----------------------------------------------------------------------------
                                $       95,513 $       55,451 $       41,553
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Great Panther Silver Limited

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME

(Expressed in Thousands of Canadian Dollars, except per share data)

For the three and nine months ended September 30, 2011 and 2010 (Unaudited)

----------------------------------------------------------------------------
----------------------------------------------------------------------------
                              Three months ended           Nine months ended
                                   September 30,               September 30,
                              2011          2010          2011          2010
----------------------------------------------------------------------------

Revenue             $      16,278 $      11,165 $      40,298 $      28,397
Cost of sales:
  Cost of sales             6,581         5,367        16,605        14,801
  Amortization and
   depletion of
   mineral
   properties,
   plant and
   equipment                1,377         1,119         2,809         2,976
----------------------------------------------------------------------------
                            7,958         6,486        19,414        17,777
----------------------------------------------------------------------------
Gross profit                8,320         4,679        20,884        10,620

General and
 administrative
 expenses                   2,134         1,550         5,505         4,169

Finance and other
 income (expenses):
  Interest income             128            40           289            83
  Finance costs               (17)         (283)         (308)         (805)
  Foreign exchange
   gain (loss)             (3,143)          303        (2,498)          706
  Other income
   (expense)                  153          (130)          177          (131)
----------------------------------------------------------------------------
                           (2,879)          (70)       (2,340)         (147)
----------------------------------------------------------------------------
Income before
 income taxes               3,307         3,059        13,039         6,304

Income tax recovery
 (expense):
  Current income
   tax recovery
   (expense)                  108            (9)         (114)         (107)
  Deferred income
   tax recovery                 -             -             -         2,198
----------------------------------------------------------------------------
                              108            (9)         (114)        2,091
----------------------------------------------------------------------------
Income for the
 period                     3,415         3,050        12,925         8,395

Other comprehensive
 income (loss), net
 of tax:
  Cumulative
   translation
   adjustment                (223)         (634)         (721)       (4,287)
  Net change in
   fair value of
   available-for-
   sale financial
   assets                     (28)            -          (134)         (107)
----------------------------------------------------------------------------
                             (251)         (634)         (855)       (4,394)
----------------------------------------------------------------------------
Comprehensive
 income for the
 period             $       3,164 $       2,416 $      12,070 $       4,001
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Earnings per share
  Basic             $        0.03 $        0.03 $        0.10 $        0.07
  Diluted           $        0.02 $        0.03 $        0.10 $        0.07

Weighted average
 number of common
 shares
  Basic               134,513,598   114,049,485   129,226,764   113,332,904
  Diluted             137,834,462   115,752,734   134,491,829   115,590,435
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Great Panther Silver Limited

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Expressed in Thousands of Canadian Dollars, except per share data)

For the three and nine months ended September 30, 2011 and 2010 (Unaudited)

----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                    Three months ended     Nine months ended
                                         September 30,         September 30,
                                       2011       2010       2011       2010
----------------------------------------------------------------------------
Cash flows provided by
 operating activities:

Income for the period           $    3,415 $    3,050 $   12,925 $    8,395

Items not involving cash:
    Amortization expenses            1,413      1,054      2,903      3,014
    Foreign exchange (gains)
     losses                          2,006         32      2,198         42
    Deferred tax liability               -          -          -     (2,197)
    Accretion on reclamation
     and remediation provision          11         10         34         33
    Share-based payments                 -        272          -        288
    Interest accretion on
     convertible loan notes              -        240        239        522
    Loss (gain) on disposal of
     capital assets                      -          -          -          1
    Shares received for mineral
     property and capital
     expenditures                        -          -          -        (23)
----------------------------------------------------------------------------
                                     6,845      4,658     18,299     10,075
Changes in non-cash operating
 working capital:
    Trade and other receivables     (3,222)    (2,134)    (4,977)    (3,683)
    Income taxes recoverable           (36)        42        (57)       165
    Inventories                        748       (193)    (3,079)      (987)
    Prepaid expenses, deposits
     and advances                      223        808       (628)       543
    Trade and other payables,
     including derivatives            (147)      (103)       (94)       606
    Current tax liability             (128)         -        (19)        57
----------------------------------------------------------------------------
    Net cash provided by
     operating activities            4,283      3,078      9,445      6,776
----------------------------------------------------------------------------

Cash flows used in investing
 activities:
    Intangible assets                 (133)         -       (454)       (32)
    Mineral properties and
     capital expenditures           (6,314)    (4,493)   (15,726)   (11,001)
    Restricted cash                    (14)      (154)        31       (154)
----------------------------------------------------------------------------
    Net cash used in investing
     activities                     (6,461)    (4,647)   (16,149)   (11,187)
----------------------------------------------------------------------------

Cash flows from financing
 activities:
    Repayment of capital lease
     obligations                       (65)      (273)      (287)      (720)
    Repayment of promissory
     notes                               -       (100)      (448)      (222)
    Repayment of convertible
     loan notes                          -        (81)       (61)       (81)
    Proceeds from exercise of
     options                           394        543      2,308      1,069
    Proceeds from exercise of
     warrants                          505          -      4,056        473
    Issuance of shares for
     cash, net of issue costs            -          -     22,500        (32)
----------------------------------------------------------------------------
    Net cash provided by
     financing activities              834         89     28,068        487
----------------------------------------------------------------------------

Effect of exchange rate changes
 on cash and cash equivalents         (342)       (39)      (257)       (24)
Increase (decrease) in cash and
 cash equivalents                   (1,686)    (1,519)    21,107     (3,948)
Cash and cash equivalents,
 beginning of period                36,760     10,883     13,967     13,312
----------------------------------------------------------------------------
Cash and cash equivalent, end
 of period                      $   35,074 $    9,364 $   35,074 $    9,364
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Contact:
B&D Capital
604-685-6465
604-899-4303 (FAX)
info@greatpanther.com
www.greatpanther.com
Posted in Investments, Medium Market Stocks, Uncategorized | Tagged | Leave a comment

Stocks to check out for tomorrow: September 22, 2011

Short List:

1. ELON (7.39): Echelon Corporation develops, markets, and sells energy control networking solutions primarily in the Americas, Europe, the Middle East, Africa, and the Asia Pacific/Japan.

Posted in Uncategorized | Tagged | Leave a comment

Factbox: Who the FHFA has sued over subprime bonds

Fri Sep 2, 2011 6:08pm EDT

(Reuters) – The U.S. Federal Housing Finance Agency sued 17 financial institutions on Friday, for allegedly misrepresenting material information when selling mortgage-backed securities.

Below is a summary of banks that were sued, and the dollar value of securities that the FHFA is suing over:

DOLLAR VALUE OF SECURITIES ($ BLNS)

Ally Financial $6

Bank of America Corp

Bank of America $6

Countrywide (unit of Bank of America) $26.6

Merrill Lynch (unit of Bank of America) $24.853

Barclays Plc $4.9

Citigroup Inc $3.5

Credit Suisse* $14.1

Deutsche Bank AG $14.2

First Horizon National Corp $0.883

General Electric Co $0.549

Goldman Sachs Group Inc $11.1

HSBC* $6.2

JPMorgan Chase & Co $33

Morgan Stanley $10.58

Nomura Holdings Inc* $2

Royal Bank of Scotland $30.4

Societe Generale $1.3

TOTAL: $196.165

*Some lawsuits targeted subsidiaries and not the parent company

Source: court documents

(Compiled by Ben Berkowitz, Clare Baldwin, Dan Wilchins and Jonathan Stempel)

Posted in Business, Current News | Leave a comment